Global Human cytomegalovirus 65 kDa Phosphoprotein market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size and Outlook 2025-31

The global Human cytomegalovirus 65 kDa Phosphoprotein market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. United States market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Human cytomegalovirus 65 kDa Phosphoprotein players cover Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Human cytomegalovirus 65 kDa Phosphoprotein Industry Forecast looks at past sales and reviews total world Human cytomegalovirus 65 kDa Phosphoprotein sales in 2024, providing a comprehensive analysis by region and market sector of projected Human cytomegalovirus 65 kDa Phosphoprotein sales for 2025 through 2031. With Human cytomegalovirus 65 kDa Phosphoprotein sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human cytomegalovirus 65 kDa Phosphoprotein industry. This Insight Report provides a comprehensive analysis of the global Human cytomegalovirus 65 kDa Phosphoprotein landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human cytomegalovirus 65 kDa Phosphoprotein portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Human cytomegalovirus 65 kDa Phosphoprotein market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human cytomegalovirus 65 kDa Phosphoprotein and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human cytomegalovirus 65 kDa Phosphoprotein. This report presents a comprehensive overview, market shares, and growth opportunities of Human cytomegalovirus 65 kDa Phosphoprotein market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; HB-101 &nbsp;&nbsp;&nbsp; CyMVectin &nbsp;&nbsp;&nbsp; ASP-0113 &nbsp;&nbsp;&nbsp; PepVax &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Brain Tumor &nbsp;&nbsp;&nbsp; Hemotaological Tumor &nbsp;&nbsp;&nbsp; Kidney Transplant Rejection &nbsp;&nbsp;&nbsp; Liver Transplant Rejection &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Astellas Pharma Inc &nbsp;&nbsp;&nbsp; Hookipa Biotech AG &nbsp;&nbsp;&nbsp; Immunomic Therapeutics Inc &nbsp;&nbsp;&nbsp; Vakzine Projekt Management GmbH &nbsp;&nbsp;&nbsp; Vaximm AG &nbsp;&nbsp;&nbsp; VBI Vaccines Inc &nbsp;&nbsp;&nbsp; Vical Inc Key Questions Addressed in this Report What is the 10-year outlook for the global Human cytomegalovirus 65 kDa Phosphoprotein market? What factors are driving Human cytomegalovirus 65 kDa Phosphoprotein market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Human cytomegalovirus 65 kDa Phosphoprotein market opportunities vary by end market size? How does Human cytomegalovirus 65 kDa Phosphoprotein break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Human cytomegalovirus 65 kDa Phosphoprotein by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Human cytomegalovirus 65 kDa Phosphoprotein by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Human cytomegalovirus 65 kDa Phosphoprotein Segment by Type &nbsp;2.2.1 HB-101 &nbsp;2.2.2 CyMVectin &nbsp;2.2.3 ASP-0113 &nbsp;2.2.4 PepVax &nbsp;2.2.5 Others &nbsp;2.3 Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type &nbsp;2.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sale Price by Type (2020-2025) &nbsp;2.4 Human cytomegalovirus 65 kDa Phosphoprotein Segment by Application &nbsp;2.4.1 Brain Tumor &nbsp;2.4.2 Hemotaological Tumor &nbsp;2.4.3 Kidney Transplant Rejection &nbsp;2.4.4 Liver Transplant Rejection &nbsp;2.4.5 Others &nbsp;2.5 Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application &nbsp;2.5.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Breakdown Data by Company &nbsp;3.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Company (2020-2025) &nbsp;3.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sale Price by Company &nbsp;3.4 Key Manufacturers Human cytomegalovirus 65 kDa Phosphoprotein Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Human cytomegalovirus 65 kDa Phosphoprotein Product Location Distribution &nbsp;3.4.2 Players Human cytomegalovirus 65 kDa Phosphoprotein Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Human cytomegalovirus 65 kDa Phosphoprotein by Geographic Region &nbsp;4.1 World Historic Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth &nbsp;4.4 APAC Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth &nbsp;4.5 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth &nbsp;4.6 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth 5 Americas &nbsp;5.1 Americas Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country &nbsp;5.1.1 Americas Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) &nbsp;5.1.2 Americas Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) &nbsp;5.2 Americas Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2020-2025) &nbsp;5.3 Americas Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region &nbsp;6.1.1 APAC Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2020-2025) &nbsp;6.1.2 APAC Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2020-2025) &nbsp;6.2 APAC Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2020-2025) &nbsp;6.3 APAC Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein by Country &nbsp;7.1.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) &nbsp;7.1.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) &nbsp;7.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2020-2025) &nbsp;7.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein by Country &nbsp;8.1.1 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Human cytomegalovirus 65 kDa Phosphoprotein &nbsp;10.3 Manufacturing Process Analysis of Human cytomegalovirus 65 kDa Phosphoprotein &nbsp;10.4 Industry Chain Structure of Human cytomegalovirus 65 kDa Phosphoprotein 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors &nbsp;11.3 Human cytomegalovirus 65 kDa Phosphoprotein Customer 12 World Forecast Review for Human cytomegalovirus 65 kDa Phosphoprotein by Geographic Region &nbsp;12.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Region &nbsp;12.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecast by Region (2026-2031) &nbsp;12.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecast by Type (2026-2031) &nbsp;12.7 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Astellas Pharma Inc &nbsp;13.1.1 Astellas Pharma Inc Company Information &nbsp;13.1.2 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Astellas Pharma Inc Main Business Overview &nbsp;13.1.5 Astellas Pharma Inc Latest Developments &nbsp;13.2 Hookipa Biotech AG &nbsp;13.2.1 Hookipa Biotech AG Company Information &nbsp;13.2.2 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Hookipa Biotech AG Main Business Overview &nbsp;13.2.5 Hookipa Biotech AG Latest Developments &nbsp;13.3 Immunomic Therapeutics Inc &nbsp;13.3.1 Immunomic Therapeutics Inc Company Information &nbsp;13.3.2 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Immunomic Therapeutics Inc Main Business Overview &nbsp;13.3.5 Immunomic Therapeutics Inc Latest Developments &nbsp;13.4 Vakzine Projekt Management GmbH &nbsp;13.4.1 Vakzine Projekt Management GmbH Company Information &nbsp;13.4.2 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Vakzine Projekt Management GmbH Main Business Overview &nbsp;13.4.5 Vakzine Projekt Management GmbH Latest Developments &nbsp;13.5 Vaximm AG &nbsp;13.5.1 Vaximm AG Company Information &nbsp;13.5.2 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Vaximm AG Main Business Overview &nbsp;13.5.5 Vaximm AG Latest Developments &nbsp;13.6 VBI Vaccines Inc &nbsp;13.6.1 VBI Vaccines Inc Company Information &nbsp;13.6.2 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 VBI Vaccines Inc Main Business Overview &nbsp;13.6.5 VBI Vaccines Inc Latest Developments &nbsp;13.7 Vical Inc &nbsp;13.7.1 Vical Inc Company Information &nbsp;13.7.2 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolios and Specifications &nbsp;13.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Vical Inc Main Business Overview &nbsp;13.7.5 Vical Inc Latest Developments 14 Research Findings and Conclusion

Report	Global Human cytomegalovirus 65 kDa Phosphoprotein Market Growth 2025-2031
Selected License	Single ID:LPI23707

Buyer Information

Order Summary